ProductsServices

PharmaceuticalEnvironment & SafetyAgro & FoodOil & GasResearch Institutes
About UsContact Us

Bacterial Endotoxin Testing BET Eclipse Suez

Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform

banner image

Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform

  • Overview
  • Key features
  • Benefits
  • Industry

Overview

The Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform is a groundbreaking solution designed to provide consistent, accurate, and reliable testing of bacterial endotoxins in pharmaceutical, biotechnological, and medical device products. With its robust analytical performance, the Eclipse platform offers a comprehensive and highly reliable approach to endotoxin testing, ensuring that products meet the strict regulatory requirements necessary for safety and efficacy.

Key Features

Regulatory Compliance:

The Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform is an advanced system that provides the highest standards of accuracy and reliability for endotoxin testing. One of its most distinctive features is the use of FDA-licensed Limulus Amebocyte Lysate (LAL), which is the gold standard reagent for bacterial endotoxins testing. The integration of LAL ensures that the Eclipse BET platform meets the stringent requirements outlined in the harmonized global pharmacopoeia (USP, EP, JP, etc.) while delivering unmatched performance and efficiency in endotoxin detection.

Precision-crafted features:

The Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform is designed not only to provide high-performance endotoxin testing but also to dramatically streamline the entire assay process. By automating several aspects of the testing procedure, the Eclipse platform offers significant operational efficiencies, reducing manual effort, costs, and time associated with traditional endotoxin testing methods. Specifically, the Eclipse platform results in: 89% Reduction in Pipetting Steps 85% Reduction in Labor 90% Reduction in Expensive LAL Reagent Us

Benefits

Fast and Efficient

Enables fully compliant, 21-sample assay setup in as little as 9 minutes

Significant Cost Savings

Reduces Limulus Amebocyte Lysate (LAL) reagent use by up to 90%

Global Compliance

Meets all requirements of the harmonized pharmacopoeia: USP <85>, EP 2.6.14 and JP 4.01

Industry

Pharmaceuticals

Pharmaceuticals

FAQs

The Sievers Eclipse BET platform uses FDA-licensed Limulus Amoebocyte Lysate (LAL) to meet all requirements of the harmonized global pharmacopoeia, including USP <85>, EP 2.6.14, and JP 4.01, ensuring consistent and compliant bacterial endotoxin testing.

The Eclipse platform dramatically streamlines the assay setup, reducing pipetting steps by 89%, labor by 85%, and LAL reagent use by up to 90%, making it both cost-effective and efficient.

The Eclipse platform enables fully compliant, 21-sample assays to be set up in as little as 9 minutes, significantly speeding up the testing process compared to traditional methods.